2011-2012

Support from Pharmaceutical Companies and Device Manufacturers and American Heart Association Total Corporate Support

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association’s finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the Better Business Bureau’s Wise Giving Alliance (WGA), the premier organization evaluating charitable organizations.

Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials. Contributions from corporations account for just 24.9 percent.

Financial support from corporations helps the association’s programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association’s corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the entire American Heart Association, including National Center, its Affiliates and local offices. It represents approximately 24.9 percent of the AHA’s $639,525,149 in total revenue (2011-2012 audited financial statements).

Support that the American Heart Association receives from pharmaceutical companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 2.4 percent of the association’s total revenue (2011-2012 audited financial statements). The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed during fiscal year 2011-2012, noting that, in some cases, the funds will be paid out in future years.

<table>
<thead>
<tr>
<th>AHA Fiscal Year 2010-2011 Revenue Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>$480,537,196</td>
</tr>
<tr>
<td>75.1%</td>
</tr>
<tr>
<td>$15,369,726</td>
</tr>
<tr>
<td>2.4%</td>
</tr>
<tr>
<td>$143,618,227</td>
</tr>
<tr>
<td>22.5%</td>
</tr>
</tbody>
</table>

- FY 11-12 Pharmaceutical, Medical Device and Insurance Contributed Income
- FY 11-12 Other Corporate Support (AHA Association-wide)
- FY 11-12 Other Sources of Revenue (AHA Association-wide)
NOTE: The Pie Chart above shows income committed in fiscal year 2011-2012 to the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers and the amount of total corporate support committed to AHA association-wide, compared to all sources of revenue.

Listed below in the middle column is cash received by the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers during fiscal year 2011-2012.

In addition, in the right column, we have listed revenue that was committed to the American Heart Association during fiscal year 2011-2012, but will actually be received in future years. An example is a multi-year sponsorship of an American Heart Association program or campaign.

<table>
<thead>
<tr>
<th>Corporation</th>
<th>Total Cash Received During FY 2011-2012 on Prior and Current Year Commitments</th>
<th>Current Year FY 2012-2012 Commitments Receivable in the Future</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Vascular</td>
<td>37,500</td>
<td>-</td>
</tr>
<tr>
<td>Accumetrics</td>
<td>32,500</td>
<td>-</td>
</tr>
<tr>
<td>Aetna</td>
<td>125,000</td>
<td>105,000</td>
</tr>
<tr>
<td>Allergan, Inc</td>
<td>295,000</td>
<td>-</td>
</tr>
<tr>
<td>Amgen</td>
<td>105,000</td>
<td>-</td>
</tr>
<tr>
<td>Amarin</td>
<td>25,000</td>
<td>300,000</td>
</tr>
<tr>
<td>Amylin/Lilly</td>
<td>30,000</td>
<td>-</td>
</tr>
<tr>
<td>Anthem Blue Cross Blue Shield</td>
<td>265,000</td>
<td>160,000</td>
</tr>
<tr>
<td>Arthrex</td>
<td>85,000</td>
<td>-</td>
</tr>
<tr>
<td>Astellas</td>
<td>99,725</td>
<td>-</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>319,250</td>
<td>215,000</td>
</tr>
<tr>
<td>Asubio</td>
<td>2,473</td>
<td>-</td>
</tr>
<tr>
<td>Bayer</td>
<td>6,512</td>
<td>150,000</td>
</tr>
<tr>
<td>Blue Cross Blue Shield</td>
<td>110,000</td>
<td>-</td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals</td>
<td>302,363</td>
<td>3,050,000</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>145,000</td>
<td>-</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Company</td>
<td>20,000</td>
<td>-</td>
</tr>
<tr>
<td>Bristol-Myers Squibb/Pfizer</td>
<td>344,500</td>
<td>-</td>
</tr>
<tr>
<td>Bristol-Myers Squibb/Sanofi Joint Venture</td>
<td>100,000</td>
<td>-</td>
</tr>
<tr>
<td>Capricor</td>
<td>2,000</td>
<td>-</td>
</tr>
<tr>
<td>Chugai</td>
<td>2,473</td>
<td>-</td>
</tr>
<tr>
<td>Cigna</td>
<td>25,000</td>
<td>430,000</td>
</tr>
<tr>
<td>Codman</td>
<td>20,000</td>
<td>-</td>
</tr>
<tr>
<td>Covidien</td>
<td>50,000</td>
<td>-</td>
</tr>
<tr>
<td>Covidien/ev3 Neurovascular</td>
<td>100,000</td>
<td>-</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>37,363</td>
<td>-</td>
</tr>
<tr>
<td>Eisai</td>
<td>2,473</td>
<td>-</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>50,000</td>
<td>-</td>
</tr>
<tr>
<td>Forest Laboratories</td>
<td>160,000</td>
<td>-</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>30,000</td>
<td>-</td>
</tr>
<tr>
<td>Company</td>
<td>Amount 1</td>
<td>Amount 2</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Genentech</td>
<td>472,500</td>
<td>55,000</td>
</tr>
<tr>
<td>Gilead</td>
<td>30,000</td>
<td>30,000</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>50,000</td>
<td>-</td>
</tr>
<tr>
<td>Great West Life</td>
<td>150,000</td>
<td>-</td>
</tr>
<tr>
<td>Harvard Pilgrim Healthcare</td>
<td>140,000</td>
<td>-</td>
</tr>
<tr>
<td>Horizon Blue Cross Blue Shield of NJ</td>
<td>35,000</td>
<td>-</td>
</tr>
<tr>
<td>Isis Pharmaceuticals</td>
<td>2,500</td>
<td>-</td>
</tr>
<tr>
<td>Janssen</td>
<td>-</td>
<td>468,000</td>
</tr>
<tr>
<td>Johnson &amp; Johnson/Listerine</td>
<td>-</td>
<td>350,000</td>
</tr>
<tr>
<td>Kaiser Permanente</td>
<td>162,500</td>
<td>-</td>
</tr>
<tr>
<td>LipoScience</td>
<td>-</td>
<td>50,000</td>
</tr>
<tr>
<td>MDCO</td>
<td>30,000</td>
<td>-</td>
</tr>
<tr>
<td>Medtronic, Inc</td>
<td>227,500</td>
<td>130,000</td>
</tr>
<tr>
<td>Merck</td>
<td>2,261,931</td>
<td>475,000</td>
</tr>
<tr>
<td>Merck (Coricidin)</td>
<td>1,085,000</td>
<td>-</td>
</tr>
<tr>
<td>Merck/Schering-Plough</td>
<td>308,363</td>
<td>-</td>
</tr>
<tr>
<td>Norvartis Pharmaceuticals</td>
<td>167,348</td>
<td>-</td>
</tr>
<tr>
<td>Norvartis KK</td>
<td>6,237</td>
<td>-</td>
</tr>
<tr>
<td>Nono Nordisk</td>
<td>57,500</td>
<td>-</td>
</tr>
<tr>
<td>Omron Healthcare, Inc</td>
<td>250,000</td>
<td>-</td>
</tr>
<tr>
<td>Ortho McNeil/Janssen</td>
<td>2,079,000</td>
<td>-</td>
</tr>
<tr>
<td>Pfizer</td>
<td>110,000</td>
<td>-</td>
</tr>
<tr>
<td>Philips</td>
<td>80,000</td>
<td>350,000</td>
</tr>
<tr>
<td>Physio-Control</td>
<td>20,000</td>
<td>-</td>
</tr>
<tr>
<td>Premera Blue Cross</td>
<td>50,000</td>
<td>50,000</td>
</tr>
<tr>
<td>PRI Healthcare/Janssen</td>
<td>-</td>
<td>50,000</td>
</tr>
<tr>
<td>Regence Blueshield of Idaho</td>
<td>40,000</td>
<td>60,000</td>
</tr>
<tr>
<td>Sanofi</td>
<td>183,750</td>
<td>-</td>
</tr>
<tr>
<td>Sanofi-Aventis</td>
<td>-</td>
<td>50,000</td>
</tr>
<tr>
<td>Schreing Corporation</td>
<td>20,000</td>
<td>-</td>
</tr>
<tr>
<td>Schering-Plough</td>
<td>187,500</td>
<td>-</td>
</tr>
<tr>
<td>Shionogi</td>
<td>6,181</td>
<td>-</td>
</tr>
<tr>
<td>Southeastern Emergency Equipment</td>
<td>50,000</td>
<td>-</td>
</tr>
<tr>
<td>Takeda</td>
<td>109,725</td>
<td>-</td>
</tr>
<tr>
<td>United Healthcare</td>
<td>755,000</td>
<td>-</td>
</tr>
<tr>
<td>WellPoint</td>
<td>4,500,000</td>
<td>-</td>
</tr>
<tr>
<td>Zoll Medical</td>
<td>25,000</td>
<td>-</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td><strong>$16,581,667</strong></td>
<td><strong>6,528,000</strong></td>
</tr>
</tbody>
</table>

Note: (1) Reflects all corporate contributions to National Center and 10 highest corporate contributions to each Affiliate.

Note (2) Column includes cash received on commitments from contracts and conferences. This was recorded as revenue in FY 2008-2009, FY 2009-2010, FY 2010-2011 and FY 2011-12.